Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.33 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881581 | 0.87 | ALOX15 (0.36) | ALOX15MEN1KMT2AALDH1A1RECQL | |
| SCHEMBL4903505 | 0.83 | MEN1 (0.33) | ALOX15MEN1KMT2AALDH1A1RECQL | |
| SCHEMBL4897575 | 0.82 | MEN1 (0.33) | ALOX15MEN1KMT2AALDH1A1RECQL | |
| SCHEMBL4901474 | 0.81 | QRFPR (0.34) | ALOX15MEN1KMT2AALDH1A1RECQL | |
| SCHEMBL6878670 | 0.80 | CES1 (0.46) | ALOX15MEN1KMT2AALDH1A1ELOVL6 | |
| SCHEMBL4903534 | 0.79 | ENPP3 (0.34) | ALOX15MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL10150725 | 0.77 | — | — | |
| SCHEMBL10150700 | 0.73 | NPSR1 (0.40) | MEN1KMT2AALDH1A1NPSR1GAA | |
| SCHEMBL10150724 | 0.72 | CES1 (0.35) | MEN1KMT2AALDH1A1NPSR1TSHR | |
| SCHEMBL4901366 | 0.70 | QRFPR (0.35) | MEN1KMT2AALDH1A1KDM4EQRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173350-B2 | Oxime compound and resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100021847-A1 | Oxime Compound and Resist Composition Containing the Same | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021847-A1 | Oxime Compound and Resist Composition Containing the Same | CYC1, UQCRB, CBR1 | ALOX15 306/4885MEN1 1580/4885KMT2A 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.